PEM/DDP对晚期非鳞肺癌患者心理状况及睡眠质量的影响及参麦注射液的作用
|
摘要
目的探讨PEM/DDP对晚期非鳞肺癌患者心理状况及睡眠质量的影响及参麦注射液的作用。方法选取2009年7月～2017年12月收治的晚期(Ⅲ～Ⅳ期)非鳞肺癌患者60例,按照治疗方法的不同随机分为研究组和对照组两组,各30例,两组患者在治疗后均接受常规生物学指标检查。研究组采用PEM/DDP化疗联合参麦注射液进行治疗,每次化疗第0～7天接受参麦注射液静脉滴注;对照组单独使用PEM/DDP化疗,每3周重复化疗,观察两组患者的治疗方法对心理状况以及睡眠质量的影响及对两组患者的不良反应。结果研究组患者的心理状况、睡眠质量、生活质量等评分显著优于对照组(P<0.05)。对照组焦虑自评量表(SAS)以及抑郁自评量表(SDS)评分分别为(35.3±3.2)分、(35.3±3.2)分,研究组SAS以及SDS评分分别为(23.2±3.1)分、(23.2±3.1)分;对照组和研究组在治疗8周后PSQI评分分别为(8.2±1.3)分、(6.9±1.1)分。研究组不良反应发生率显著低于对照组(P<0.05)。结论 PEM/DDP化疗联合参麦注射液治疗晚期非鳞肺癌患者的临床疗效显著,对患者的心理状况、睡眠质量有改善作用,可提高晚期非鳞肺癌患者的生活质量,值得推广与应用。
Objective To explore the effect of PEM/DDP on the psychological status and sleep quality of patients with advanced non-squamous lung cancer and the effect of Shenmai injection. Methods 60 patients with advanced(Ⅲ-IV)non-squamous lung cancer from July 2009 to December 2017 were randomLy divided into two groups including the study group and the control group according to the treatment method, with 30 patients in each group. Two groups underwent routine biological indicators examination. The study group was treated with PEM/DDP chemotherapy combined with Shenmai injection. The method was to receive intravenous infusion of Shenmai injection on the 0 th-7 th day of each chemotherapy, and the control group was treated with PEM/DDP chemotherapy alone every three weeks. The effects of treatment methods on psychological status and sleep quality were compared between the two groups, and the adverse reactions of the two groups were compared. Results The psychological status, sleep quality,quality of life and other scores of the two groups were compared. The scores of psychological status, sleep quality and quality of life of the study group were also significantly better than those of the control group(P<0.05). The self-rating anxiety scale(SAS)and the self-rating depression scale(SDS) scores of the control group were(35.3±3.2) and(35.3±3.2).And the scores of SAS and SDS of the study group were(23.2±3.1),(23.2±3.1) respectively. The PSQI scores of the control group and the study group were(8.2±1.3) and(6.9±1.1) after 8 weeks of treatment. The incidence of adverse reactions bewteen the two groups was compared. The incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05). Conclusion PEM/DDP chemotherapy combined with Shenmai injection is effective in the treatment of patients with advanced non-squamous lung cancer, which can improve the psychological status and sleep quality,and improved the quality of life of patients with advanced non-squamous lung cancer, and is worthy of promotion and application.
Objective To explore the effect of PEM/DDP on the psychological status and sleep quality of patients with advanced non-squamous lung cancer and the effect of Shenmai injection. Methods 60 patients with advanced(Ⅲ-IV)non-squamous lung cancer from July 2009 to December 2017 were randomLy divided into two groups including the study group and the control group according to the treatment method, with 30 patients in each group. Two groups underwent routine biological indicators examination. The study group was treated with PEM/DDP chemotherapy combined with Shenmai injection. The method was to receive intravenous infusion of Shenmai injection on the 0 th-7 th day of each chemotherapy, and the control group was treated with PEM/DDP chemotherapy alone every three weeks. The effects of treatment methods on psychological status and sleep quality were compared between the two groups, and the adverse reactions of the two groups were compared. Results The psychological status, sleep quality,quality of life and other scores of the two groups were compared. The scores of psychological status, sleep quality and quality of life of the study group were also significantly better than those of the control group(P<0.05). The self-rating anxiety scale(SAS)and the self-rating depression scale(SDS) scores of the control group were(35.3±3.2) and(35.3±3.2).And the scores of SAS and SDS of the study group were(23.2±3.1),(23.2±3.1) respectively. The PSQI scores of the control group and the study group were(8.2±1.3) and(6.9±1.1) after 8 weeks of treatment. The incidence of adverse reactions bewteen the two groups was compared. The incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05). Conclusion PEM/DDP chemotherapy combined with Shenmai injection is effective in the treatment of patients with advanced non-squamous lung cancer, which can improve the psychological status and sleep quality,and improved the quality of life of patients with advanced non-squamous lung cancer, and is worthy of promotion and application.
引文
[1]王蓉,李大鹏,冯军.参麦注射液联合化疗对晚期非小细胞肺癌患者T细胞亚群及细胞因子的影响[J].南京中医药大学学报,2016,32(2):125-128.
[2]王学敏,张维红,杜伟娇,等.阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析[J].中国肺癌杂志,2017,20(11):761-768.
[3]曲雅静,李广欣,徐丽,等.DC-CIK联合化疗治疗中晚期非小细胞肺癌临床效果评价[J].解放军医药杂志,2015,(11):72-76.
[4]杨继雷,姚秀叶,谷伟,等.参麦注射液联合左卡尼汀对慢性肺源性心脏病心肺功能的影响[J].中国临床药理学杂志,2016,32(5):396-398.
[5]魏晓晨,朱立勤,王春革,等.参麦注射液预防恶性肿瘤化疗所致周围神经毒性效果的系统评价[J].山东医药,2016,56(28):45-47.
[6]罗进光,张嘉宁,王智彬,等.参麦注射液与曲美他嗪和左卡尼汀联合治疗急性病毒性心肌炎的临床疗效及对血清TNF-α和IL-6水平的影响[J].中华医院感染学杂志,2017,27(3):576-579.
[7]邹子元,张小利,许信杰,等.基于LUX-Lung试验的阿法替尼在晚期非小细胞肺癌临床应用的研究进展[J].肿瘤,2017,37(7):801-806.
[8]郭晓斌,李晓,冯可青.老年早期非小细胞肺癌患者外周血中鳞状细胞癌相关抗原、癌胚抗原及细胞角蛋白19血清片段21-1水平的变化[J].中国老年学杂志,2017,37(4):920-921.
[9]门翔,党强,段秋立,等.甲状腺转录因子-1对不同化疗方案治疗晚期肺腺癌患者的预后价值研究[J].中国呼吸与危重监护杂志,2018,6(1):59-65.
[10]马汉宸,隋东昕,徐少华.晚期肺腺癌培美曲塞联合顺铂化疗后应用培美曲塞同药维持治疗的临床疗效[J].山东医药,2016,56(33):99-101.
[11]李长生,任中海.培美曲塞联合顺铂一线治疗晚期肺腺癌疗效及安全性分析[J].中华肿瘤防治杂志,2016,23(18):1250-1253.
[12]张朝巍.贝伐单抗与培美曲塞、顺铂联合治疗晚期肺腺癌的临床效果及对VEGF的影响[J].山东医药,2017,57(25):90-92.
[13]周磊磊,张大红,岳顺.培美曲塞联合顺铂与多西他赛联合顺铂方案在局部晚期非小细胞肺癌同步放化疗效对比[J].中华肿瘤防治杂志,2016,4(s1):109-110.
[14]兰杰.培美曲塞联合顺铂对晚期非小细胞肺癌患者血清VEGF-C、IL-6、MMP9表达的影响[J].中国地方病防治杂志,2017,4(6):701-702.
[15]杨雪飞,叶知锋,张晓丽,等.益气养阴散结方联合EGFR-TKIs治疗EGFR-TKIs继发耐药的晚期非小细胞肺癌的临床研究[J].中华中医药学刊,2018,13(2):442-445.
[16]朱亚宁,张鹏,张丹,等.评估吉非替尼交替化疗对比化疗治疗Ⅳ期非小细胞肺癌的疗效及安全性[J].中国医院药学杂志,2016,36(6):480-484.
[17]刘思远,李志鹏,郑心.肺抑瘤合剂联合AP化疗方案治疗非小细胞肺癌临床疗效观察[J].中国实验方剂学杂志,2018,(3):185-190.
[18]陈小兵,冯杰,陈小菊,等.厄洛替尼联合多烯紫杉醇-卡铂治疗晚期非小细胞肺癌的临床研究[J].现代生物医学进展,2014,(21):4063-4066.
[19]王盈.用于治疗胶质母细胞瘤的培美曲塞和miR-21反义寡核苷酸共递送阳离子固体脂质纳米粒的研制和表征[J].中国医药工业杂志,2018,(1):48-49.
[20]贺红杰,宋磊,赵丹懿,等.雷替曲塞联合奥沙利铂经TACE治疗不可切除肝癌患者的疗效评价[J].介入放射学杂志,2016,25(1):40-43.
[2]王学敏,张维红,杜伟娇,等.阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析[J].中国肺癌杂志,2017,20(11):761-768.
[3]曲雅静,李广欣,徐丽,等.DC-CIK联合化疗治疗中晚期非小细胞肺癌临床效果评价[J].解放军医药杂志,2015,(11):72-76.
[4]杨继雷,姚秀叶,谷伟,等.参麦注射液联合左卡尼汀对慢性肺源性心脏病心肺功能的影响[J].中国临床药理学杂志,2016,32(5):396-398.
[5]魏晓晨,朱立勤,王春革,等.参麦注射液预防恶性肿瘤化疗所致周围神经毒性效果的系统评价[J].山东医药,2016,56(28):45-47.
[6]罗进光,张嘉宁,王智彬,等.参麦注射液与曲美他嗪和左卡尼汀联合治疗急性病毒性心肌炎的临床疗效及对血清TNF-α和IL-6水平的影响[J].中华医院感染学杂志,2017,27(3):576-579.
[7]邹子元,张小利,许信杰,等.基于LUX-Lung试验的阿法替尼在晚期非小细胞肺癌临床应用的研究进展[J].肿瘤,2017,37(7):801-806.
[8]郭晓斌,李晓,冯可青.老年早期非小细胞肺癌患者外周血中鳞状细胞癌相关抗原、癌胚抗原及细胞角蛋白19血清片段21-1水平的变化[J].中国老年学杂志,2017,37(4):920-921.
[9]门翔,党强,段秋立,等.甲状腺转录因子-1对不同化疗方案治疗晚期肺腺癌患者的预后价值研究[J].中国呼吸与危重监护杂志,2018,6(1):59-65.
[10]马汉宸,隋东昕,徐少华.晚期肺腺癌培美曲塞联合顺铂化疗后应用培美曲塞同药维持治疗的临床疗效[J].山东医药,2016,56(33):99-101.
[11]李长生,任中海.培美曲塞联合顺铂一线治疗晚期肺腺癌疗效及安全性分析[J].中华肿瘤防治杂志,2016,23(18):1250-1253.
[12]张朝巍.贝伐单抗与培美曲塞、顺铂联合治疗晚期肺腺癌的临床效果及对VEGF的影响[J].山东医药,2017,57(25):90-92.
[13]周磊磊,张大红,岳顺.培美曲塞联合顺铂与多西他赛联合顺铂方案在局部晚期非小细胞肺癌同步放化疗效对比[J].中华肿瘤防治杂志,2016,4(s1):109-110.
[14]兰杰.培美曲塞联合顺铂对晚期非小细胞肺癌患者血清VEGF-C、IL-6、MMP9表达的影响[J].中国地方病防治杂志,2017,4(6):701-702.
[15]杨雪飞,叶知锋,张晓丽,等.益气养阴散结方联合EGFR-TKIs治疗EGFR-TKIs继发耐药的晚期非小细胞肺癌的临床研究[J].中华中医药学刊,2018,13(2):442-445.
[16]朱亚宁,张鹏,张丹,等.评估吉非替尼交替化疗对比化疗治疗Ⅳ期非小细胞肺癌的疗效及安全性[J].中国医院药学杂志,2016,36(6):480-484.
[17]刘思远,李志鹏,郑心.肺抑瘤合剂联合AP化疗方案治疗非小细胞肺癌临床疗效观察[J].中国实验方剂学杂志,2018,(3):185-190.
[18]陈小兵,冯杰,陈小菊,等.厄洛替尼联合多烯紫杉醇-卡铂治疗晚期非小细胞肺癌的临床研究[J].现代生物医学进展,2014,(21):4063-4066.
[19]王盈.用于治疗胶质母细胞瘤的培美曲塞和miR-21反义寡核苷酸共递送阳离子固体脂质纳米粒的研制和表征[J].中国医药工业杂志,2018,(1):48-49.
[20]贺红杰,宋磊,赵丹懿,等.雷替曲塞联合奥沙利铂经TACE治疗不可切除肝癌患者的疗效评价[J].介入放射学杂志,2016,25(1):40-43.